Critical Comparison: AquaBounty Technologies (NASDAQ:AQB) & Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) and AquaBounty Technologies (NASDAQ:AQB – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations.

Profitability

This table compares Halozyme Therapeutics and AquaBounty Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Halozyme Therapeutics 26.93% 751.81% 23.84%
AquaBounty Technologies N/A -174.01% -43.18%

Institutional and Insider Ownership

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 8.9% of AquaBounty Technologies shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by insiders. Comparatively, 1.0% of AquaBounty Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Halozyme Therapeutics and AquaBounty Technologies”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Halozyme Therapeutics $1.40 billion 7.82 $316.89 million $3.93 24.38
AquaBounty Technologies $2.47 million 1.97 -$18.49 million ($0.69) -1.35

Halozyme Therapeutics has higher revenue and earnings than AquaBounty Technologies. AquaBounty Technologies is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Halozyme Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, AquaBounty Technologies has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Halozyme Therapeutics and AquaBounty Technologies, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Halozyme Therapeutics 1 5 7 0 2.46
AquaBounty Technologies 1 0 0 0 1.00

Halozyme Therapeutics currently has a consensus target price of $108.18, indicating a potential upside of 12.92%. Given Halozyme Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Halozyme Therapeutics is more favorable than AquaBounty Technologies.

Summary

Halozyme Therapeutics beats AquaBounty Technologies on 12 of the 13 factors compared between the two stocks.

About Halozyme Therapeutics

(Get Free Report)

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

About AquaBounty Technologies

(Get Free Report)

AquaBounty Technologies was a biotechnology company focused on developing land-based aquaculture and genetically engineered Atlantic salmon. Its best-known product, AquAdvantage Salmon, was designed to grow to market size faster than conventional farmed Atlantic salmon. The company raised salmon in recirculating aquaculture systems, which filter and reuse water. Its operations included facilities in the United States and Canada, and it developed its business around supplying salmon to the North American market.

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.